Corazon Mining Limited

CZN

Corazon Mining Ltd. is an exploration company, which engages in the exploration of nickel, cobalt, copper and gold. The company is headquartered in Perth, Western Australia. The company went IPO on 2005-06-30. The firm is an explorer advancing the Lynn Lake Nickel-Copper-Cobalt Sulfide Project in Manitoba, Canada, as well as the Mt Gilmore cobalt-copper-gold (Mt Gilmore) and Miriam nickel Sulfide projects (Miriam) in Australia. The Lynn Lake Nickel-Copper-Cobalt Sulfide Project is a significant Class-1 nickel resource. The Mt Gilmore Project is located 35 kilometers from the city of Grafton in north-eastern New South Wales. The firm owns an 80% interest in Mt Gilmore. Mt Gilmore is focused on multiple rare, cobalt-rich sulfide deposits, similar to Cobalt Ridge. The Miriam comprises five Prospecting License applications (P15/6135 to P15/6139 inclusive) and is located approximately 10 kilometers south-southwest of Coolgardie on an ultramafic trend, which hosts Auroch Minerals’ Miriam and Nepean Nickel Deposits.

CZR Resources Ltd

CZR

CZR Resources Ltd. engages in mineral exploration. The company is headquartered in Perth, Western Australia. The company went IPO on 2006-08-29. Its projects include Croydon, Yarraloola, Buddadoo, Shepherd’s Well, and Yarrie. The Croydon project is located in the Mallina Basin between Karratha and Port Hedland. The project covers approximately 40 kilometers (km) strike of the Mallina Basin, about 50 km south-east of Hemi. The Yarraloola Iron Ore Project is located 140 km southwest of Karratha, and 100 km east of Onslow. The company hosts two distinct types of iron-ore mineralization: magnetite in the Ashburton Prospect and channel iron-ore in the Robe Mesa. The Buddadoo Project covers 125 square kilometers (kms2) approximately 200 km east of the port of Geraldton in the mid-west region of Western Australia. Shepherd’s Well Project is a multi-commodity prospect located 75 km south of Karratha. The Yarrie project includes geology that extends from the BHP-owned Yarrie iron ore operation about 180 km east of Port Hedland and 90 km north-east of Marble Bar in the Pilbara.

Cynata Therapeutics Limited

CYP

Cynata Therapeutics Ltd. engages in the development and commercialization of therapeutic products. The firm is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.